Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature

Related Experiment Video

Updated: Apr 11, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K

Taxiarchis V Kourelis1, Jan C Buckner2, Naseema Gangat1

  • 1Division of Hematology, Mayo Clinic, Rochester, Minnesota.

American Journal of Hematology
|May 27, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.1K

Related Experiment Videos

Last Updated: Apr 11, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.2K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.1K

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

363
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
363
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.6K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.6K

Articles linked to this work by shared authors, journal, and citation graph.

Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome.

British journal of haematology·2025

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy.

Haematologica·2025

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.

American journal of hematology·2025

Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly.

Blood reviews·2025

A mutant ASXL1-BAP1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic monomyelocytic leukemia.

Proceedings of the National Academy of Sciences of the United States of America·2025

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.

American journal of hematology·2024

Efficacy and Safety of NTQ5082 in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria.

American journal of hematology·2026

Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.

American journal of hematology·2026

Integrated Multi-Omic Characterization of Hexokinase-1 Deficiency in Red Blood Cells Reveals Altered Redox Homeostasis, Membrane Remodeling, and Features of Incomplete Erythroid Maturation.

American journal of hematology·2026

Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.

American journal of hematology·2026

Circulating Biomarkers Associated With Hereditary Hemorrhagic Telangiectasia Sensitive to ALK1 Modulation.

American journal of hematology·2026

New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.

American journal of hematology·2026

Ropeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.

Expert review of hematology·2026

Paving the way for translational relevance in advanced therapies in Brazil: conference report from SBINT 2025.

Regenerative medicine·2026

Intrapleural instillation of tranexamic acid to control pleural hemorrhage complicating tissue plasminogen activator administration: case report.

Therapeutic advances in respiratory disease·2026

Immobilization of Microbial Transglutaminase for the Production of Homogeneous Immunotherapeutic Antibody-Drug Conjugates.

Acta naturae·2026

Correction: miR-133a-3p/TRPM4 axis improves palmitic acid induced vascular endothelial injury.

Frontiers in pharmacology·2026

First clinical implementation of histotripsy for liver tumors in Japan.

Global health & medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us